379 related articles for article (PubMed ID: 17940379)
21. Propantheline protects the oral mucosa after high-dose ifosfamide, carboplatin, etoposide and autologous stem cell transplantation.
Oblon DJ; Paul SR; Oblon MB; Malik S
Bone Marrow Transplant; 1997 Dec; 20(11):961-3. PubMed ID: 9422475
[TBL] [Abstract][Full Text] [Related]
22. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
23. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma.
Thieblemont C; Dumontet C; Saad H; Roch N; Bouafia F; Arnaud P; Hequet O; Espinouse D; Salles G; Roy P; Eljaafari-Corbin A; Du Manoir-Baumgarten C; Coiffier B
Bone Marrow Transplant; 2002 Dec; 30(11):769-75. PubMed ID: 12439700
[TBL] [Abstract][Full Text] [Related]
24. Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
Perkins JB; Effenbein GJ; Fields KK
Semin Oncol; 1996 Jun; 23(3 Suppl 6):42-6. PubMed ID: 8677448
[TBL] [Abstract][Full Text] [Related]
25. ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience.
Jerkeman M; Leppä S; Kvaløy S; Holte H
Eur J Haematol; 2004 Sep; 73(3):179-82. PubMed ID: 15287915
[TBL] [Abstract][Full Text] [Related]
26. New developments in conditioning regimens before auto-SCT in multiple myeloma.
Moreau P; Attal M; Harousseau JL
Bone Marrow Transplant; 2011 Jul; 46(7):911-5. PubMed ID: 21358678
[TBL] [Abstract][Full Text] [Related]
27. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
28. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
29. Outpatient high-dose melphalan in multiple myeloma patients.
Kassar M; Medoff E; Seropian S; Cooper DL
Transfusion; 2007 Jan; 47(1):115-9. PubMed ID: 17207239
[TBL] [Abstract][Full Text] [Related]
30. Radiation-associated pneumonitis following autologous stem cell transplantation: predictive factors, disease characteristics and treatment outcomes.
Chen CI; Abraham R; Tsang R; Crump M; Keating A; Stewart AK
Bone Marrow Transplant; 2001 Jan; 27(2):177-82. PubMed ID: 11281387
[TBL] [Abstract][Full Text] [Related]
31. [Successful treatment with high dose chemotherapy following peripheral blood stem cell transplantation for relapsed Burkitt's lymphoma with central nervous system involvement].
Yamao H; Kondo E; Miura A; Mizuno H; Yuge M
Rinsho Ketsueki; 1998 Nov; 39(11):1121-6. PubMed ID: 9866425
[TBL] [Abstract][Full Text] [Related]
32. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
McCann S; Schwenkglenks M; Bacon P; Einsele H; D'Addio A; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vorkurka S; Quinn B; Blijlevens N;
Bone Marrow Transplant; 2009 Jan; 43(2):141-7. PubMed ID: 18776926
[TBL] [Abstract][Full Text] [Related]
33. [High-dose chemotherapy with autologous peripheral blood stem cell transplantation for the treatment of multiple myeloma refractory to conventional chemotherapy].
Shimokawa T; Kajiguchi T; Saito M; Kojima Y; Takeyama H
Gan To Kagaku Ryoho; 2003 Feb; 30(2):251-4. PubMed ID: 12610874
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas.
Schlemmer M; Wendtner CM; Falk M; Abdel-Rahman S; Licht T; Baumert J; Straka C; Hentrich M; Salat C; Hiddemann W; Issels RD
Oncology; 2006; 71(1-2):32-9. PubMed ID: 17344669
[TBL] [Abstract][Full Text] [Related]
35. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
[TBL] [Abstract][Full Text] [Related]
36. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
37. Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults.
Lee SH; Son MH; Sung KW; Choi YB; Lee NH; Yoo KH; Koo HH; Lim DH; Shin HJ
J Neurooncol; 2014 Dec; 120(3):507-13. PubMed ID: 25108776
[TBL] [Abstract][Full Text] [Related]
38. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
39. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
40. Early stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide.
Johny A; Song KW; Nantel SH; Lavoie JC; Toze CL; Hogge DE; Forrest DL; Sutherland HJ; Le A; Nitta JY; Barnett MJ; Smith CA; Shepherd JD; Nevill TJ
Biol Blood Marrow Transplant; 2006 Apr; 12(4):480-9. PubMed ID: 16545732
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]